Maruho planning Japanese submission for pruritus therapy

Maruho said it will submit a regulatory application in Japan for nemolizumab after reporting that the compound met the primary endpoint in a Japanese Phase III trial to treat pruritus associated with atopic dermatitis. The company did not disclose a timeline for the submission.

Maruho Co. Ltd. (Osaka, Japan) said nemolizumab significantly improved pruritus visual analog scale (VAS) score from baseline to week 16 vs. placebo. Nemolizumab also met the secondary endpoint of improving Eczema Area and Severity Index (EASI) score at week 16 vs. placebo. The trial enrolled 215 atopic dermatitis patients with moderate-to-severe pruritus...